Researchers working at the Flanders Institute for Biotechnology and Ghent University in Belgium are due to start human trials for their flu virus vaccine. The drug is promising because it is aiming to be a universal vaccine for all the “A” type strains of the virus. It is designed to replace the currently yearly administered vaccines and provide a lifelong protection against the disease.
Trials at this stage aim to verify the safety of the vaccine and provide an insight into its influence on the immune system. The scientists goal is for two administrations to be sufficient for a lifelong protection against the virus.
